Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

New CEO Should Right InVivo's Ship

Conversation With New CEO Encourages

Yesterday we had a 30-minute conversation with InVivo Therapeutics' (NASDAQ:NVIV) new CEO, Michael J. Astrue. Mr. Astrue took over as head of InVivo back in late August 2013 when former CEO, CFO, and Chairman, Francis M. Reynolds, resigned for an undisclosed medical condition. What exactly the medical condition was that caused Mr. Reynolds to resign, or whether or not he was effectively forced out by the board and disgruntled shareholders, remains a mystery to outsiders. However, worth noting, only a few weeks later, acting CFO, Sean F. Moran, also resigned. Gregory D. Perry was appointed interim CFO in mid-September 2013. Below we provide a brief background for both Mr. Astrue and

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details